AstraZeneca pays $1.24bn for antidepressant drug

Second-biggest British pharma group in deal with US biotech firm Targacept

AstraZeneca is to spend up to $1.24bn on the rights to an experimental antidepressant drug as it expands its pipeline of neuroscience treatments, the group said yesterday.

The Anglo-Swedish group has agreed a deal with US biotech company Targacept for the development of a treatment currently known as TC-5214. AstraZeneca will pay $200m in upfront fees, and $540m as the drug hits regulatory milestones before gaining a licence.

The final tranche, worth $500m to the North Carolina-based group, will be made if sales targets are hit. Targacept is also entitled to royalties on sales under the terms of the deal.

TC-5214 has already negotiated the second phase of trials, with final tests set for the middle of next year. AstraZeneca said yesterday that it hopes to get a licence to launch the drug by 2012, undertaking to pay 80 per cent of the costs associated with getting the treatment to market.

"The deal highlights AstraZeneca's long-term commitment to the depression market and if development is successful should enhance the company's franchise in this key market," said Savvas Neophytou, an analyst at Panmure Gordon. "Depression represents a significant franchise for AstraZeneca, with its depression drug Seroquel accounting for 15 per cent of [estimated] 2009 revenues. If successful this the drug will strengthen the AstraZeneca's depression franchise."

AstraZeneca, the UK's second-biggest pharmaceutical group, believes that the benefits of strengthening its presence in the market for depression drugs are potentially huge. According to the company, 42 million people worldwide suffer from Major Depressive Disorder, the type of the illness that TC-5214 is designed to treat. The worldwide antidepressant market is worth more than $20bn a year to the pharmaceutical industry.

"The opportunity to improve treatment in depression is a large one, both commercially and in terms of benefits for patients," said AstraZeneca's chief executive, David Brennan. "It's an area both AstraZeneca and Targacept know well and I'm pleased to be adding another late-stage project to our pipeline."

Like several large pharmaceutical groups, AstraZeneca is desperate to strengthen its pipeline of drugs as products that have contributed strong profits in the past face greater competition from generic drug makers. Seroquel, which also treats schizophrenia, was AstraZeneca's second-best selling treatment last year, behind Nexium, a heartburn drug.

TC-5214 is a nicotinic channel blocker that works in a different way to most antidepressants. Targacept was spun out of the research arm of RJ Reynolds Tobacco in 2000 and specialises in developing drugs that affect the brain in similar ways to tobacco products.

Start your day with The Independent, sign up for daily news emails
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Neil Pavier: Management Accountant

£45,000 - £55,000: Neil Pavier: Are you looking for your next opportunity for ...

Sheridan Maine: Commercial Accountant

£45,000 - £55,000: Sheridan Maine: Are you a newly qualified ACA/ACCA/ACMA qua...

Laura Norton: Project Accountant

£50,000 - £60,000: Laura Norton: Are you looking for an opportunity within a w...

Laura Norton: Project Accountant

£50,000 - £60,000: Laura Norton: Are you looking for an opportunity within a w...

Day In a Page

Is a quiet crusade to reform executive pay bearing fruit?

Is a quiet crusade to reform executive pay bearing fruit?

Dominic Rossi of Fidelity says his pressure on business to control rewards is working. But why aren’t other fund managers helping?
The King David Hotel gives precious work to Palestinians - unless peace talks are on

King David Hotel: Palestinians not included

The King David is special to Jerusalem. Nick Kochan checked in and discovered it has some special arrangements, too
More people moving from Australia to New Zealand than in the other direction for first time in 24 years

End of the Aussie brain drain

More people moving from Australia to New Zealand than in the other direction for first time in 24 years
Meditation is touted as a cure for mental instability but can it actually be bad for you?

Can meditation be bad for you?

Researching a mass murder, Dr Miguel Farias discovered that, far from bringing inner peace, meditation can leave devotees in pieces
Eurovision 2015: Australians will be cheering on their first-ever entrant this Saturday

Australia's first-ever Eurovision entrant

Australia, a nation of kitsch-worshippers, has always loved the Eurovision Song Contest. Maggie Alderson says it'll fit in fine
Letterman's final Late Show: Laughter, but no tears, as David takes his bow after 33 years

Laughter, but no tears, as Letterman takes his bow after 33 years

Veteran talkshow host steps down to plaudits from four presidents
Ivor Novello Awards 2015: Hozier wins with anti-Catholic song 'Take Me To Church' as John Whittingdale leads praise for Black Sabbath

Hozier's 'blasphemous' song takes Novello award

Singer joins Ed Sheeran and Clean Bandit in celebration of the best in British and Irish music
Tequila gold rush: The spirit has gone from a cheap shot to a multi-billion pound product

Join the tequila gold rush

The spirit has gone from a cheap shot to a multi-billion pound product
12 best statement wallpapers

12 best statement wallpapers

Make an impact and transform a room with a conversation-starting pattern
Paul Scholes column: Does David De Gea really want to leave Manchester United to fight it out for the No 1 spot at Real Madrid?

Paul Scholes column

Does David De Gea really want to leave Manchester United to fight it out for the No 1 spot at Real Madrid?
Season's finale brings the end of an era for top coaches and players across the continent

The end of an era across the continent

It's time to say farewell to Klopp, Clement, Casillas and Xavi this weekend as they move on to pastures new, reports Pete Jenson
Bin Laden documents released: Papers reveal his obsession with attacking the US and how his failure to keep up with modern jihad led to Isis

'Focus on killing American people'

Released Bin Laden documents reveal obsession with attacking United States
Life hacks: The innovations of volunteers and medical workers are helping Medécins Sans Frontières save people around the world

Medécins Sans Frontières's life hacks

The innovations of volunteers and medical workers around the world are helping the charity save people
Ireland's same-sex marriage vote: As date looms, the Irish ask - how would God vote?

Same-sex marriage

As date looms, the Irish ask - how would God vote?
The underworld is going freelance: Why The Godfather's Mafia model is no longer viable

The Mafia is going freelance

Why the underworld model depicted in The Godfather is no longer viable